Japanese Chemical Makers Strengthens Overseas Medical Business To Offset Sluggish Chemical Demand
This article was originally published in PharmAsia News
Executive Summary
Amid the worldwide recession, several Japanese chemical companies strengthened their medical businesses to offset a sluggish demand for chemical and optical products. Asahi Chemical signed a co-development and promotion deal with Nagano-based medical device maker Misuzu Sun Medical Holdings for Evaheart left ventricular assist system for congestive heart failure patients in overseas markets. The company has submitted an application with FDA to start clinical trials in the U.S. Trials are also being planned in Europe in 2011. The company estimates ¥25 billion in sales by 2020. Sekisui Chemical is in negotiations to acquire a mid-sized U.S. company and expand its diabetes testing agent market. Teijin established a joint venture in Spain this February to strengthen its home care device business. (Click here for more - Japanese language
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.